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Abstract. We have studied the impact of transmission electron microscopy (TEM) and low
dose electron diffraction on ten different crystalline pharmaceutical compounds, covering a
diverse chemical space and with differing physical properties. The aim was to establish if
particular chemical moieties were more susceptible to damage within the electron beam. We
have measured crystalline diffraction patterns for each and indexed nine out of ten of them.
Characteristic electron dosages are reported for each material, with no apparent correlation
between chemical structure and stability within the electron beam. Such low dose electron
diffraction protocols are suitable for the study of pharmaceutical compounds.
1. Introduction
The performance of pharmaceuticals is highly dependent on the structure and purity of the active
pharmaceutical ingredient (API). It is essential to fully understand and characterize the solid state
properties of pharmaceutical materials, different polymorphs (different crystal structures of the same
compound) can exhibit different effects in the body and may require different processing and storage
conditions. Characterization includes understanding what crystal forms and impurities are present
within the material and in what quantity. Currently the conventional ways to determine the properties
of materials are to use techniques such as powder X-ray diffraction (pXRD). These techniques are
very useful for analyzing bulk materials however, current detection limits make it difficult to analyze
trace amounts (<1%), materials with low crystallinity or nano-sized crystalline particles.
Transmission electron microscopy (TEM) can be applied to the characterization of
pharmaceuticals, for example, through analysis of individual particles by electron diffraction, the
identification of amorphous and crystalline phases present at low concentrations and identification of
different polymorphs [1]. The diffraction patterns yield information on the symmetry and unit cell
dimensions of the crystalline form within the material, ultimately characterizing the API and
distinguish between different crystal structures. Through analysis of particles or crystals of different
morphology, trace impurities can be identified and analyzed using TEM; by electron diffraction,
energy dispersive X-ray (EDX) spectroscopy and potentially electron energy loss spectroscopy
(EELS).
A major problem in TEM analysis of pharmaceuticals is alteration or damage due to the electron
beam, especially for structurally sensitive specimens such as biological materials, polymers and
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organic crystals. There are two main causes of beam damage that occur in TEM, elastic and inelastic
scattering events [2, 3].
Elastic scattering occurs when electrons interact with the electrostatic field of atomic nuclei, and
can result in atomic displacement or electron-beam sputtering. Inelastic scattering is caused by
electron-electron interactions and can result in ionization damage (radiolysis) of the sample, this
causes chemical bonds to break and change the structure of the specimen. Other forms of damage that
can be caused by both elastic and inelastic scattering include electrostatic charging, hydrocarbon
contamination and heating of the specimen [2, 3].
For organic compounds radiolysis is the main form of radiation damage and in some crystalline
specimens this results in a decrease in crystallinity, evident in a fading electron diffraction pattern.
Previous work on organic compounds has shown conjugated ring systems increase the stability of the
compound in the electron beam probably due to improved intermolecular bonding [4]. Replacing
hydrogen atoms with halides such as chlorine and fluorine has also been shown to improve the
stability of organic compounds possibly due to an increase in steric interactions stopping other atoms
from moving once chemical bonds have been broken [5].
In this study we investigated ten different crystalline pharmaceutical compounds covering a diverse
chemical space and with differing physical properties to characterise and determine which chemical
structures are more susceptible to electron beam damage.
2. Experimental
All the samples were provided by AstraZeneca after checking the crystallinity by pXRD. Samples
were prepared for TEM by suspending the non-soluble powders in water and placing a drop onto an
Ar/O2 plasma treated, continuous carbon TEM grid and allowing it to air dry. The grids were
examined by TEM (FEI Tecnai F20), operated at 200 kV and equipped with a Gatan Orius CCD
camera using a standard room temperature characterization protocol established by Pan et al. [6].
Briefly, the flux of electrons was given by the irradiation time and beam intensity which was
controlled by the condenser lens and electron source (extraction voltage, gun lens and spot size)
settings.
The characteristic dose (electron dose when the intensity of the brightest diffraction spot falls to a
value of 1/e) was obtained from a plot of normalized diffraction spot intensity versus electron fluence.
The electron fluence was calculated for each diffraction pattern from the exposure time and electron
beam current using a procedure described by Pan et al. [6] and the spot intensities were normalized
against the most intense spot.
3. Results and Discussion
Diffraction pattern series were successfully gathered for ten compounds and characteristic dosages
determined (Table 1). For the compounds with known structures the experimental diffraction patterns
were indexed to a specific zone axis despite not lying in an exact orientation (Figure 1).
Figure 1: (a) Electron
diffraction pattern from an
indapamide crystal
oriented close to the [110]
zone axis, recorded with
an electron flux of 3.59
electrons nm-2 s-1 (b) [110]
pattern simulation using
CrystalMaker software and
indapamide structure listed
in Table 1.
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Table 1: Characteristic dosages (averages and standard deviation of three or more measurements) of
specific diffraction spots for each pharmaceutical compound investigated, obtained from normalized
intensity versus electron fluence plots (Figure 3).
As mentioned earlier diffraction spots fade as the cumulative dose increases due to the loss of
crystallinity within the specimen. In some series, diffraction spots increase in intensity after the initial
exposure and then sharply decrease towards zero (Figure 2) this is most probably due to movement/re-
orientation of the crystal when irradiated.
Crystallinity decays with a number of different trends as shown by the normalised diffraction spot
intensity versus cumulative electron fluence plots (Figure 3). The spot intensities increase and then
decrease rapidly (Figure 3a), suggesting re-orientation of a crystal. Figure 3b shows the behaviour
from the same sample but uses the ( ) spot rather than the ( ) spot. This plot shows a rapid
decrease in intensity similar to the previous plot but without the movement/re-orientation. The values
of characteristic dose are similar when estimated from each plot. The final trend is shown in both
Figure 3c and 3d where there is a decrease in spot intensity followed by a stable plateau and then
another decrease. An inverse power-law can be fitted to the final decrease at high fluence in each of
the plots in Figure 3, similar to the fitting by Pan et al. who studied the electron beam induced damage
of haemosiderin cores containing ferrihydrite [6].
When relating the structures of the pharmaceuticals (Table 1) to the average characteristic doses
there are no obvious trends that describe the stability of molecular crystals in the electron beam. This
includes characteristic dose and factors such as conjugated rings or halogens, which have been
previously shown to increase the stability [4, 5]. Hence, there must be other parameters that contribute
to the stability of the organic crystals. Possibilities include the lattice enthalpy (stability of crystal) or
enthalpy of sublimation which relates to the intermolecular interactions within the crystal structure [8].
Compound Chemical Formula Characteristic Dose (e-
/nm2)
Miller Indices
(hkl)
CSD Refcode
[7]
Tolnaftate C19H17NOS 2079 ±40 No available
structure
No available
structure
Griseofulvin C17H17ClO6 1620 ±160 011 GRISFL02
Indapamide C16H16ClN3O3S 571 ±40 FOCCAD
Bicalutamide C18H14F4N2O4S 454 ±20 002 JAYCES
Cilostazol C20H27N5O2 297 ±85 124 XOSGUH01
Felodipine C18H19Cl2NO4 294 ±40 DONTIJ
Dutasteride C27H30F6N2O2 220 ±80 220 LATSIK
Amcinonide C28H35FO7 130 ±20 VAYJOW
Probucol C31H48O2S2 37 ±10 020 HAXHET01
Efavirenz C14H9ClF3NO2 33 ±10 211 AJEYAQ02
Figure 2: Diffraction pattern series of indapamide initially oriented on the [110] zone axis with
electron flux of 3.59 electrons nm-2 s-1 at 45, 120, 170 and 250 seconds after initial exposure to the
electron beam. The pattern changes to a systematic row after 120s before fading, consistent with a
change in orientation of the crystal as well as a decrease in crystallinity.
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4. Conclusion
A low electron dose diffraction protocol for the characterization of pharmaceuticals has been
successfully used giving indexed diffraction patterns and initial data on characteristic doses. The next
challenge is to extend this protocol to drug formulations. Location of the API in the formulation
matrix could also be identified by imaging, diffraction and even spectroscopy (EDX or EELS). Firstly,
electron diffraction undertaken within the previously established dose limits can be used to determine
the final crystal structure of the API. Secondly, API crystals which are nano-sized, and are therefore
difficult to characterise by pXRD, could be characterised using this approach.
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Figure 3: Normalized diffraction spot intensity versus cumulative electron fluence for specific
diffraction spots in three different compounds. Red line is the fitting of the inverse power law and
the blue line represents the value of 1/e (a) ( ) indapamide (b) ( ) indapamide (c) tolnaftate,
unknown diffraction spot (d) ( ) griseofulvin.
(a) (b)
(c) (d)
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